scout

Ian Flinn, MD, Sarah Cannon Research Institute

Articles by Ian Flinn, MD, Sarah Cannon Research Institute

Novel Therapies for R/R Follicular Lymphoma

ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

ZUMA-5 in R/R Follicular Lymphoma

ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.

Emerging Therapies for R/R Follicular Lymphoma

ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.

Latest Updated Articles